Abstract. Ovarian cancer, especially epithelial ovarian cancer (EOC), which accounts for 90% of ovarian cancer, continues to be the leading cause of death among gynecological malignancies. However, the factors associated with its malignant biological behavior are still poorly understood. Accumulating evidence suggests that microRNAs (miRNAs), regulating diverse biological processes, may play an important role in tumorigenesis and development. miR-21 has been frequently observed to be aberrantly overexpressed in various tumors. Using real-time PCR, we confirmed that miR-21 was significantly overexpressed in human EOC tissues and cell lines. The overexpression of miR-21 correlated with histological differentiation, clinicopathological stage, and lymph node metastasis, and we showed that knockdown of miR-21 by an inhibitor caused a significant reduction in cell proliferation and decrease in cell migration and invasion abilities. Furthermore, we demonstrated that knockdown of miR-21 significantly increased the expression of PTEN, a known tumor suppressor in ovarian cancer. Collectively, our findings suggest miR-21 may be important in the initiation and progression of EOC as an oncomiR, likely through regulating PTEN.

Introduction

miRNAs are a class of small non-coding RNA molecules, 20-22 nucleotides in length, that regulate gene expression by direct cleavage of the targeted mRNAs or by inhibiting translation through perfect or nearly perfect complementarity to targeted mRNAs at the 3'-untranslated regions (UTRs). Previous studies show that more than half of the miRNAs can be aligned to genomic fragile sites or regions associated with cancers (1), which indicates that miRNAs might play an important role in cancer pathogenesis, development, and metastasis. Aberrant expression of miRNA has been reported in various tumors such as breast, lung, liver, colon and gastric cancer indicating that there is a close correlation between miRNAs and human malignancy (2-5).

Many studies suggest that miR-21 is aberrantly overexpressed and function as an oncomiR in diverse tumors, including ovarian cancer (6-8). How miR-21 affects cancer development and progression is still not well understood. Si et al (8) reported that mir-21 promotes growth of the breast cancer cell line MCF-7 both in vitro and in vivo, which may be due to the ability of miR-21 to suppress the expression of the tumor suppressor PTEN and TPM1 (9). Meng et al (10) found that the overexpression of miR-21 stimulates increased migration and invasion through targeting the PTEN tumor suppressor gene in hepatocellular carcinoma cells, suggesting that PTEN might be a target gene for miR-21. However, the role and relevant pathway of miR-21 in ovarian carcinogenesis is largely unknown. Frequent inactivation of PTEN has been implicated in ovarian cancer (11,12). However, PTEN mutations, promoter methylation and LOH at PTEN locus are not main causes for PTEN inactivation (13,14). The mechanisms of down-regulation of PTEN expression in ovarian cancer remain unclear.

In our present study, we observed a significant overexpression of miR-21 in epithelial ovarian cancer (ECO) tissues and OVCAR-3 cell lines. The effect of miR-21 on cell proliferation, migration, and invasion ability were further investigated. Moreover, we found PTEN was negatively correlated with miR-21 in EOC tissues and significantly regulated by miR-21 OVCAR-3 cell lines. Our results suggested that miR-21 may function as an oncomiR in tumorigenesis and progression in ovarian cancer by targeting PTEN expression.
purchased from the Shanghai cell library of Academia Sinica Type Culture Collection. A total of 87 tissue samples, including 48 epithelial ovarian cancer tissues, 24 benign ovarian epithelial cysts, and 15 normal ovarian tissue sections were collected by surgery at the Affiliated Hospital of Qingdao University Medical College. Ethical approval was obtained from the Institutional Review Boards, and informed consent for the use of tissues was obtained for all individuals. One part was snap-frozen in liquid nitrogen and stored at -80˚C, and the other part was fixed in 10% formalin. The histopathological diagnoses were determined using the WHO criteria, and the tumor histotypes included 28 serous, 14 mucinous, and six endometrioid carcinomas. All tumors were staged according to the International Federation of Gynecology and Obstetrics standards (FIGO). Stage breakdown was: n=5 for stage I, n=11 for stage II, n=23 for stage III, and n=9 for stage IV. None of the patients received chemotherapy, radiotherapy, or hormone therapy before the surgical operation.

**Construction of a short-hairpin RNA targeted miR-21 expression vector.** A short-hairpin RNA specifically targeting miR-21 was constructed as follows: From the microbase databank (http://www.mirbase.org/cgi-bin/mira), we obtained two mature fragment sequences for miR-21 and synthesized the following short anti-mir-21 RNA oligonucleotides:

- **miR-21-1**: 5’-gatccCAACATCAGTCTGATAAGCttcaagagaGCTTATCAGACTGATGTTGTTTTTTg-3’
- **miR-21-2**: 5’-gatccCAGCCCATCGACTGGTGTTAtcaagagaAACACCAGTCGATGGGCTGTTTTTTg-3’
- **miR-21-neg**: 5’gatccGGCGCATAAGAAGCATATAttcaagagaTATATGCTTCTTATGCGCCTTTTTTg-3’

All the sequences were evaluated for sequence specificity by a BLAST search and did not show homology to other known genes. Annealed oligonucleotides were ligated with vector Linear pSIREN-RetroQ, resulting in three recombinants: pSIREN-miR-21-1, pSIREN-miR-21-2, and pSIREN-miR-21-Neg. The recombinants were identified by restriction endonuclease analysis and DNA sequencing, respectively.

**Cell culture and transfection.** OVCAR-3 cells were cultured in McCoy’s 5A medium with 10% fetal bovine serum, 100 U/ml penicillin, and 100 μg/ml streptomycin, and incubated at 37˚C in a humidified atmosphere containing 5% CO₂. Twenty-four hours prior to transfection, cells were seeded in 6-well plates at a density of 5x10⁵ cells/well and grown to 60% confluence. OVCAR-3 cells were transfected using the Lipofectamine 2000 reagent according to the manufacturer’s instructions. Briefly, pDsRed (7 μl/100 μl) was mixed with pSIREN-miR-21-1, pSIREN-miR-21-2, and pSIREN-miR-21-Neg. The recombinants were identified by restriction endonuclease analysis and DNA sequencing, respectively.

**Isolation of total RNA.** RNA was extracted from cell lines and frozen tissue samples using the TRIzol reagent (Invitrogen Life Technologies) according to the manufacturer’s instructions. The dissolved RNA was stored at -70˚C before use. RNA quality was assessed with a NanoDrop1000 spectrophotometer (NanoDrop Technologies).

---

**Table I. Primers used for real-time RT-PCR assay.**

<table>
<thead>
<tr>
<th>Target</th>
<th>Primer</th>
<th>Sequence</th>
</tr>
</thead>
<tbody>
<tr>
<td>hsa-miR-21-1</td>
<td>RT</td>
<td>5’GTCGTATCCAGTGCGTGGAGTGGAGTCGGCAATTGCACTGGATACGACTCAACATC3’</td>
</tr>
<tr>
<td></td>
<td>F primer</td>
<td>5’GCCGGTAGTTATCAGACTGA3’</td>
</tr>
<tr>
<td></td>
<td>R primer</td>
<td>5’TGCGTGTCGAGGAGTC3’</td>
</tr>
<tr>
<td>hsa-miR-21-2</td>
<td>RT</td>
<td>5’GTCGTATCCAGTGCGTGGAGTGGAGTCGGCAATTGCACTGGATACGACACAGCCC3’</td>
</tr>
<tr>
<td></td>
<td>F primer</td>
<td>5’GCCGCAACACATCGAGATG3’</td>
</tr>
<tr>
<td></td>
<td>R primer</td>
<td>5’TGCGTGTCGAGGAGTC3’</td>
</tr>
<tr>
<td>U6</td>
<td>F primer</td>
<td>5’GCTTTCGCGACACATATACTAAAAT3’</td>
</tr>
<tr>
<td></td>
<td>R primer</td>
<td>5’CGCCTCACAGAATTGCGGTGTCAT3’</td>
</tr>
</tbody>
</table>

*a hsa-miR-21-1, primers for expression of miR-21 both in frozen EOC tissues and in OVCAR-3 cells; b hsa-miR-21-2, primers only for expression of miR-21 in OVCAR-3 cells.*
Real-time RT-PCR for miR-21 quantification. We designed gene-specific looped primers for RT-PCR (listed in Table I). Reverse transcription of RNA used 1 μg total RNA in a Gene Amp PCR System 9700 (Applied Biosystems) in a total volume of 20 μl. The reaction proceeded for 30 min at 16°C, 42 min at 42°C, 5 min at 85°C and the cDNA was stored at -20°C. Real-time PCR was performed using SYBR Green I (Invitrogen) detection chemistry on a Rotor-Gene 3000 real-time PCR machine (Corbett Research). The reactions were amplified for an initial 5-min denaturation step at 95°C, followed by 40 cycles of 10 sec at 95°C, 20 sec at 60°C, 20 sec at 72°C and 20 sec at 78°C for collecting fluorescence. Real-time PCR for the U6 gene was performed in the same manner as the corresponding primers. All the reactions were typically run in duplicate three times, simultaneously. The cycle number at which the fluorescent signal in each reaction tube crossed a threshold (CT) was determined for miR-21 and the relative amount of miR-21 in tumor tissue to that in control was described using the equation 2-ΔΔCT, where ΔΔCT = CT miR-21 - CT U6 - (CT miR-21 - CT U6) control group.

Immunohistochemistry. PTEN was detected using a mouse monoclonal antibody (ZM 0221, 1:100, Zhongshan Technology, Binnjin, China). After antigen preparation and blocking in 10% goat serum, the specimens were incubated overnight at 4°C with primary antibodies (100X diluted). After washing, the slides were incubated with rabbit biotinylated antibody for 30 min at 37°C. Immunostaining was revealed with the SP (streptavidin peroxidase) system (Zhongshan Technology) using diaminobenzidine as a chromogen. The slides were counter-stained with hematoxylin before mounting. PBS replaced the primary antibody for the negative control and a known breast cancer slide was used as the positive control. For the assessment of staining, five fields were randomly selected and their scores were averaged. The percentage of tumor cytoplasm showing positive staining for PTEN was recorded and scored as follows: a score of 0 for 0% staining, 1 for staining of <10%, 2 for 10-50%, 3 for 50-80%, and 4 for >80%. The average intensity, corresponding to the presence of negative, weak, intermediate, and strong staining, was given a score from 0 to 3, respectively. The positive cell score was added to the average intensity to form an additive score for semiquantitative assessment as follows: regardless of the intensity of staining, a positive cell score <10% for negative, a score of 3 for +, 4-5 for ++, 6-7 for +++.

Western blotting. Cells were washed twice with ice-cold PBS and lysed on the culture dishes using lysis buffer (20 mM Tris pH 7.5, 150 mM NaCl, 1% Triton X-100, 10% protease inhibitors). The protein concentration was determined using the BCA method and 20 μg of each sample was separated by SDS-PAGE (10 and 4%) and transferred to PVDF membranes. Non-specific binding sites were blocked by incubating with 5% BSA solution for 1 h at room temperature. The membranes were then incubated with rabbit anti-human PTEN antibody (1:6000) and rabbit anti-β-actin polyclonal antibody (1:1000) overnight at 4°C. Anti-rabbit secondary antibodies conjugated to horseradish peroxidase were used at a dilution of 1:2000. The protein was visualized using ECL Western blotting detection reagents and analyzed by scanning densitometry by Smart View Analysis Software (Shanghai Furi Science & Technology Co. Ltd.).

Cell proliferation assays. Cell proliferation was assessed using an MTT assay. Cells (5.0x10⁵ cells/well) were seeded on 96-well plates. At a series of time points, 10 μl of MTT was added to each well and the cells were incubated at 37°C for 4 h. Then, 100 μl dimethylsulfoxide of the dimethyl sulfoxide was added to each well. The plates were shaken for 30 sec. The optical density (OD) was measured at 570 nm by using a microplate reader (Bio-Rad Model 680, Richmond, CA, USA).

Scratch-wound assay. The cells were plated onto six-well plates at a concentration of 1x10⁵ cells per well. Cell monolayers were carefully wounded by scratching with a sterile plastic pipette tip. The cells were washed twice with cooled PBS and incubated for 24 h. For each wound, 5 fields of excursion were photographed at 0, and 48 h after treatment.

Cell invasion assay. Cells (2.5x10⁴ cells per well) were seeded onto the top chamber of a 24-well matrigel-coated polyethylene terephthalate membrane inserts with 8 μm pores (Corning). The bottom chamber was filled with 0.6 ml McCoy’s 5A with 10% FBS as a chemoattractant. After incubation for 24 h, the filter membrane was fixed with 100% methanol and stained with hematoxylin and eosin. The degree of invasiveness was quantified by counting the number of cells in 10 random fields of view per filter, using x400 magnification. Data obtained from three separate inserts are shown as mean values.

Statistical analysis. Data analyses were performed with the statistical software package SPSS 13.0. The Student t-test was used to assess miR-21 expression between different groups. The correlations between miR-21 or PTEN expression and the clinicopathological features were assessed with a Chi-square (χ²) test when appropriate. A Spearman rank correlation coefficient test was used for the correlation between miR-21 with PTEN expression. The level of statistical significance was set at p<0.05.

Results

Expression of miR-21 in different ovarian tissue samples. The Ct values of miR-21 in ovarian epithelial carcinomas were lower than those in benign ovarian cysts and normal ovarian tissues. The results shown in Fig. 1 indicate that, among the 48 ovarian cancer samples analyzed, the relative expression of miR-21 (2-ΔΔCT = 4.849±1.813) was significantly up-regulated by 4-fold or more compared with the benign ovarian cysts (1.133±0.291) and normal ovarian tissues (1.057±0.126) (p<0.01, respectively). No differences were observed in miR-21 relative expression between benign ovarian cysts and normal controls.

miR-21 overexpression in relation to clinicopathological features. As shown in Table II, the relative expressions of miR-21 were significantly higher in advanced stage and
grade 3 tumor samples compared to the early stage and grade 1 to 2 tumor samples \(2^{-\Delta\Delta CT} = 5.603\pm1.787\) vs. \(3.341\pm0.254\) and \(2^{-\Delta\Delta CT} = 7.057\pm1.552\) vs. \(3.845\pm0.680\), \(p<0.01\) respectively). The same differences were observed between the lymph node positive group and negative group \(2^{-\Delta\Delta CT} = 7.095\pm1.728\) vs. \(4.100\pm1.070, p<0.01\). However,
we did not observe any significant differences in the three histotypes considered.

**miR-21 overexpression is associated with decreased PTEN protein levels in ovarian cancer patients.** As shown in Table III, 20 of 48 (41.66%) ovarian cancer tissues were positive for PTEN, mainly weakly positive and expressed in the cytoplasm (Fig. 2), which was distinctly lower than that in benign ovarian cysts and normal controls. Moreover, eight of 32 (25%) stage III-IV tissue samples were positive for PTEN, which was lower than that in stage I-II tissue samples (12/16, 75%). Three of 28 (10.71%) grade 3 tissue samples and two of 12 (16.66%) lymph node positive samples were positive for PTEN, which are obviously lower compared with grade 1-2 samples (17/20, 85%) and lymph node negative samples (20/36, 55.55%) (Table II).

Table III. Immunohistochemical profiling of PTEN in epithelial ovarian cancers, benign ovarian cysts, and normal ovarian tissues.

<table>
<thead>
<tr>
<th>Group</th>
<th>Staining intensity</th>
<th>Positive cases (%)</th>
<th>$\chi^2$</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Normal (n=15)</td>
<td>-</td>
<td>0</td>
<td>2</td>
<td>6</td>
</tr>
<tr>
<td>Benign (n=24)</td>
<td>+</td>
<td>4</td>
<td>5</td>
<td>10</td>
</tr>
<tr>
<td>EOC (n=48)</td>
<td>++</td>
<td>28</td>
<td>12</td>
<td>8</td>
</tr>
</tbody>
</table>

0, +, ++ and +++ indicate negative, weak, moderate and strong immunostaining intensity, respectively. Of 48 ovarian cancer tissues, 20 (41.66%) were positive for PTEN, mainly weakly positive expression, which was distinctly lower than that in benign ovarian cysts and normal control. Chi-square ($\chi^2$) test was used to analyze the data. $p \leq 0.05$ was considered as statistically significant.

Table IV. Correlation between miR-21 overexpression and PTEN in epithelial ovarian cancer.

<table>
<thead>
<tr>
<th>PTEN</th>
<th>miR-21 (n=48)</th>
<th>Negative (n=28)</th>
<th>Positive (n=20)</th>
</tr>
</thead>
<tbody>
<tr>
<td>miR-21</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Negative</td>
<td>3.410±0.261</td>
<td>7 (33.3)</td>
<td>14 (66.6)</td>
</tr>
<tr>
<td>Positive</td>
<td>5.967±1.711</td>
<td>21 (77.77)</td>
<td>6 (22.22)</td>
</tr>
</tbody>
</table>

Spearman rank correlation coefficient test was used for the data. The statistically significant negative correlation between miR-21 and PTEN was, $r = -0.447$, $p < 0.01$.

miR-21 overexpression is associated with decreased PTEN protein levels in ovarian cancer patients.
negatively correlated with miR-21 expression ($r = -0.447, p<0.01$) (Table IV).

**Construction and identification of short-hairpin RNA expression vectors.** When the annealed oligos (59 bp) were inserted downstream of the H1 promoter of the empty vector pSIREN-RetroQ, the recombinant vectors could be digested by *Bam*HI/*Bgl*II and *Eco*RI/*Bgl*II restriction enzymes to produce 263 bp and 322 bp fragments, respectively. When the recombinants were digested only by *Bam*HI or *Eco*RI, no fragment was produced (Fig. 3). The recombinant vectors were then identified by DNA sequencing.

pSIREN-miR-21-1 and pSIREN-miR-21-2 efficiently suppressed miR-21 expression. Seventy-two hours after infection, all the pSIREN-miR-21 recombinants were mixed with pDsRed, respectively, and transfected into OVCAR-3 cells (Fig. 4). Decreased miR-21 expression was confirmed by real-time RT-PCR. Data showed that miR-21 expression levels decreased significantly both in pSIREN-miR-21-1 and pSIREN-miR-21-2 infected cells compared to pSIREN-miR-21-Neg infected cells and control group (Fig. 5).

**miR-21 modulates PTEN expression in OVCAR-3 cells.** To test whether PTEN was directly modulated by miR-21, Western blotting was used to detect PTEN expression in OVCAR-3 cells after transfection. The data showed that PTEN expression was increased in OVCAR-3 cells transfected by pSIREN-miR-21-1 and pSIREN-miR-21-2, respectively, compared with vector-control transfected cells (Fig. 6), indicating that inhibition of miR-21 can significantly increase PTEN expression in OVCAR-3 cell lines.

**Down-regulation of miR-21 expression inhibits OVCAR-3 cell proliferation in vitro.** Cell viability following transfection with pSIREN-miR-21 was tested by MTT assay after 72 h. As
showed in Fig. 7, there was no significant difference for light absorption values between pSIREN-miR-21-neg group and the control group. The inhibition rate in pSIREN-miR-21-1 and pSIREN-miR-21-2 group was higher than that in control group (23.9, 29.4 and 9.03%, respectively), indicating the cell proliferation ability was suppressed by transfection of pSIREN-miR-21-1 and -2.

miR-21 inhibits OVCAR-3 cells migration and invasion in vitro. In scratch-wound assay, we observed the scratched areas were mostly covered with cells both in blank control and negative control group, while there were fewer cells covered in pSIREN-miR-21-1 and pSIREN-miR-21-2 group (Fig. 8). To further quantitatively evaluate the effect of down-regulation of miR-21 in cell invasion, a transwell assay was performed. As shown in Fig. 9, the migrated cells in pIREN-miR-21-1 and pSIREN-miR-21-2 group were 40±3.56 and 29.5±2.38 respectively, and the number was significantly lower than that in control group (73±2.16) (p<0.05). No significant difference was observed between control group and pSIREN-miR-21-net group (69±1.83). The data indicate cell migration and invasion were significantly suppressed after being transfected with pSIREN-miR-21-1 and pSIREN-miR-21-2.

Discussion

Accumulated evidence has associated the aberrant expression of many miRNAs, including miR-21, with various cancers and certain oncogenes or tumor suppressors involved in tumorigenesis (15,16). However, the potential role and regulation mechanism of miRNAs in ovarian cancer are not well demonstrated. In this study, we showed that miR-21 was significantly up-regulated in epithelial ovarian cancer (EOC), suggesting that miR-21 may function as an oncogene in the pathogenesis of ovarian cancer.

Moreover, overexpression of miR-21 was closely correlated with advanced clinical stage, high grade, and lymph node metastases which are the main prognostic factors for ovarian cancer, implying miR-21 might be involved in the development and metastasis of cancer, and has a prognostic implication for EOC. We further demonstrated that knock-down of miR-21 could dramatically decrease cell proliferation, invasion and migration abilities in OVCAR-3 cells. Our data suggest that the aberrant expression of miR-21 directly affects invasive and metastatic potential of tumor cells and is implicated in the progression of ovarian cancer.

Previous studies have reported that miR-21 plays an important role not only in tumor growth but also in the invasion and metastasis by targeting multiple tumor/metastasis suppressor genes including PTEN, PDCD4, BCL-2 and TPM1 (9,10,17). PTEN, well known for its role in tumor growth, invasion and metastasis, has been reported as a tumor suppressor gene in ovarian cancer (13,18). Our study shows that 41.66% of EOC samples were positive for PTEN
expression and 58.34% were negative that is consistent with previous studies (18,19). PTEN expression show a negative correlation with the expression of miR-21 in EOC tissues. Furthermore, we demonstrated that inhibition of miR-21 can significantly increase PTEN expression in OVCAR-3 cell lines, suggesting epithelial ovarian cancer might enhance malignant biological behavior by inactivating PTEN genetically and up-regulating miR-21.

PTEN is capable of restricting growth and survival signals by limiting the activity of the phosphoinositide 3-kinase (PI3K) pathway. A decrease in functional PTEN causes constitutive activation of downstream components of the PI3K

Figure 8. The effect of down-regulation of miR-21 on OVCAR-3 cell migration (48 h after transfection, x100). White line, 0 h; (A) control group; (B) pSIREN-miR-21-net group; (C) pSIREN-miR-21-1 group; (D) pSIREN-miR-21-2 group.

Figure 9. The effect of down-regulation of miR-21 on OVCAR-3 cell invasion (x400). (A) control group; (B) pSIREN-miR-21-net group; (C) pSIREN-miR-21-1 group; (D) pSIREN-miR-21-2 group.
pathway including Akt, leading to tumor progression and metastasis (20). Thus, PTEN down-regulation by miR-21 may contribute to transformation and increased tumor cell survival (20). Meng et al (10) previously demonstrated that miR-21 can modulate gene expression directly at the PTEN 3′-UTR and that PTEN might be a potential target for miR-21. The inhibition of miR-21 using antisense oligonucleotides increased the expression level of PTEN in hepatocellular carcinoma cells (21). Zhu et al (22) also reported that miR-21 was implicated in invasion and metastases in breast cancer through decreasing the expression of PTEN. Therefore, our data together with other studies indicate that the mechanism by which miR-21 promotes tumor invasion and metastasis through down-regulating PTEN expression is a very important regulation pathway not only involved in ovarian cancer tumorigenesis and progression but also in other tumors.

Besides PTEN gene, several other genes have also been identified as targets of miR-21. For example, Chan and his colleagues reported that miR-21 was remarkably up-regulated in human glioblastoma and contributed to the malignant phenotype by blocking expression of PDCD4 gene (23). Zhu et al (9) identified a tumor suppressor TPM-1 as a potential target of miR-21. Therefore, the miR-21-mediated pathways appear to be very complex in various physiological and pathological process and tumorigenesis.

In conclusion, our study revealed a different expression profile for miR-21 in EOC tissue specimens compared with benign ovarian cysts and normal ovarian tissues. We show, for the first time, that overexpression of miR-21 is significantly correlated with negative expression of PTEN protein in EOC tissue specimens and cell lines. Aberrant expression of miR-21 can alter multiple biological processes of OVCAR-3 cells such as proliferation, migration, and invasion, probably through regulating PTEN. It is suggested that miR-21 functions as an ancomiR involved in EOC tumorigenesis and promotes invasion and metastasis. Therefore, targeting miR-21 may provide a better strategy for blocking tumor metastasis.

Acknowledgements

We would like to thank Dr Xingsheng Yang (Qilu Hospital of Shandong University, Jinan, China) for his critical reading of the manuscript and thank Mr. Haijing Tu for excellent technical support.

References